Related Experiment Video
Updated: Jun 21, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
Published on: July 14, 2016
Plasma complement components and activation fragments: associations with age-related macular degeneration genotypes
Robyn Reynolds1, M Elizabeth Hartnett, John P Atkinson
1Ophthalmic Epidemiology and Genetics Service, Department of Ophthalmology, Tufts University School of Medicine, Tufts Medical Center, Boston, Massachusetts 02111, USA.
Insights
Increased levels of complement activation fragments Bb and C5a are linked to advanced age-related macular degeneration (AMD). These findings suggest the alternative complement pathway plays a role in AMD development.
Area of Science:
- Ophthalmology
- Immunology
- Genetics
Background:
- Age-related macular degeneration (AMD) is a leading cause of vision loss.
- Genetic factors, particularly those in the complement system, are known risk factors for AMD.
- The role of circulating complement activation markers in AMD pathogenesis requires further investigation.
Purpose of the Study:
- To determine if circulating complement activation and regulation markers are independently associated with advanced AMD.
- To investigate the relationship between these complement markers and AMD genotypes.
Main Methods:
- Plasma and DNA samples from advanced AMD patients (geographic atrophy and neovascular AMD) and controls were analyzed.
- Plasma levels of complement components and activation fragments were measured.
- Genotyping for AMD-associated single-nucleotide polymorphisms was performed, and logistic regression was used to assess associations.
Main Results:
- Elevated levels of Bb and C5a fragments were significantly associated with advanced AMD.
- The alternative pathway regulator CFH showed an inverse association with AMD.
- Body mass index (BMI) was positively associated with several complement components and fragments.
- C5a fragment levels correlated with specific AMD genotypes (LOC387715/ARMS2 and C3).
Conclusions:
- Increased Bb and C5a fragment levels are independent risk factors for advanced AMD.
- Higher BMI is linked to elevated complement component levels.
- The alternative complement pathway appears to be actively involved in AMD pathogenesis.
- Inclusion of C3a, Bb, and C5a enhances predictive models for AMD.
Purpose:
Several genes encoding complement system components and fragments are associated with age-related macular degeneration (AMD). This study was conducted to determine whether alterations in circulating levels of these markers of complement activation and regulation are also independently associated with advanced AMD and whether they are related to AMD genotypes.
Methods:
Plasma and DNA samples were selected from individuals in our AMD registry who had progressed to or developed the advanced stages of AMD, including 58 with geographic atrophy and 62 with neovascular disease. Subjects of similar age and sex, but without AMD, and who did not progress were included as controls (n = 60). Plasma complement components (C3, CFB, CFI, CFH, and factor D) and activation fragments (Bb, C3a, C5a, iC3b, and SC5b-9) were analyzed. DNA samples were genotyped for seven single-nucleotide polymorphisms in six genes previously shown to be associated with AMD: CFB, CFH, C2, C3, and CFI and the LOC387715/ARMS2 gene region. The association between AMD and each complement biomarker was assessed by using logistic regression, controlling for age, sex, and proinflammatory risk factors: smoking and body mass index (BMI). Functional genomic analyses were performed to assess the relationship between the complement markers and genotypes. Concordance, or C, statistics were calculated to assess the effect of complement components and activation fragments in an AMD gene-environment prediction model.
Results:
The highest quartiles of Bb and C5a were significantly associated with advanced AMD, when compared with the lowest quartiles. In multivariate models without genetic variants, the odds ratio (OR) for Bb was 3.3 (95% confidence interval [CI] = 1.3-8.6), and the OR for C5a was 3.6 (95% CI = 1.2-10.3). With adjustment for genetic variants, these ORs were substantially higher. The alternative pathway regulator CFH was inversely associated with AMD in the model without genotypes (OR = 0.3; P = 0.01). Positive associations were found between BMI and plasma C3, CFB, CFH, iC3b, and C3a. There were also significant associations between C5a fragment and LOC387715/ARMS2 and C3 genotypes (P for trend = 0.02, 0.04), respectively. C statistics for models with behavioral and genetic factors increased to 0.94 +/- 0.20 with the addition of C3a, Bb, and C5a.
Conclusions:
Increased levels of activation fragments Bb and C5a are independently associated with AMD. Higher BMI is related to increased levels of complement components. C5a is associated with AMD genotypes. C statistics are stronger with the addition of C3a, Bb, and C5a in predictive models. Results implicate ongoing activation of the alternative complement pathway in AMD pathogenesis.
Related Concept Videos
Complement System
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

